Shots:

• GENFIT to acquire all the share capital & voting rights of Versantis incl. initial consideration of $41.35M, ~$67.22M upon achievement of clinical & regulatory milestones and one-third of the net proceeds from the potential sale of a Priority Review Voucher of VS-01’s pediatric application. The transaction is expected to close in Q4’22
• The acquisition will combine Versantis’ expertise with GENFIT’s programs in liver diseases to advance R&D. The acquisition expands GENFIT’s pipeline with VS-01-ACLF (P-II program), VS-01-UCD, a pediatric program for UCD & VS-02-HE, an early-stage program for HE
• The acquisition also strengthens GENFIT’s position as a leader in ACLF with the addition of clinically advanced assets. GENFIT will develop TS-01 for ammonia

Ref:  Versantis  Image:  Versantis